Vistagen to Present at the Jefferies Global Healthcare Conference
29 Maio 2024 - 9:30AM
Business Wire
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical
company pioneering neuroscience to deliver groundbreaking therapies
for individuals affected by psychiatric and neurological disorders,
today announced that company management will present and host
one-on-one meetings during the Jefferies Global Healthcare
Conference taking place June 5 and 6, 2024 in New York City.
Jefferies Global Healthcare Conference
- Shawn Singh, Chief Executive Officer, will participate in a
fireside chat on Thursday, June 6 at 11:00 a.m. Eastern Time.
A webcast will be accessible through the “Events” page in the
“Investors” section of the Company’s website at www.Vistagen.com.
Investors interested in arranging a one-on-one meeting during the
conference should contact their Jefferies representative.
About Vistagen
Vistagen (Nasdaq: VTGN) is a biopharmaceutical company
pioneering neuroscience to deliver groundbreaking therapies for
individuals affected by psychiatric and neurological disorders.
Five of Vistagen’s clinical-stage neuroscience pipeline candidates
belong to a new class of drugs known as pherines, which are
investigational neuroactive nasal sprays with innovative proposed
mechanisms of action that activate chemosensory neurons in the
nasal passages to impact fundamental neural circuitry in the
olfactory system and the brain without the need for systemic
absorption or binding to receptors in the brain. Vistagen’s sixth
investigational candidate is an oral prodrug with potential to
modulate NMDA receptor activity. At Vistagen, we are passionate
about delivering differentiated treatments that set new standards
of care for people living with anxiety, depression, and other
neurological disorders. Connect at www.Vistagen.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240529702427/en/
Investors: Mark A. McPartland Vistagen Therapeutics
markmcp@vistagen.com
Media: Caren Scannell Vistagen Therapeutics
cscannell@vistagen.com
Vistagen Therapeutics (NASDAQ:VTGN)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Vistagen Therapeutics (NASDAQ:VTGN)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024